ÂÜÀòÂÒÂ×

Ali Zeaiter serves as the VP of Oncology Clinical Development at Alentis Therapeutics since July 2025 and has been the Chief Medical Officer and Co-Founder at Superior Nano since May 2024. Previously, Ali held the position of Head of Clinical Development Oncology at Servier for a brief period in 2018 and served as Vice President of Clinical Development & Regulatory Affairs at PharmaMar from May 2022 to February 2025. Ali's extensive experience also includes a significant tenure at F. Hoffmann-La Roche Ltd from 2010 to March 2018, where responsibilities included leading global development for Tarceva and directing clinical development plans for multiple early-stage molecules. Ali began foundational training as a Medical Oncologist at Assistance Publique Hopitaux de Paris from 2002 to 2006 and completed medical education at The Russian State Medical University, Université de Paris VII, and Université de Paris XI.